Impact of efavirenz on intestinal metabolism and transport: Insights from an interaction study with ezetimibe in healthy volunteers

Clinical Pharmacology and Therapeutics

Volumn 91, Issue 3, 2012, Pages 506-513

  Oswald, S ^a   Meyer Zu Schwabedissen, H E ^a   Nassif, A ^a   Modess, C ^a   Desta, Z ^b   Ogburn, E T ^b   Mostertz, J ^a   Keiser, M ^a   Jia, J ^a   Hubeny, A ^a   Ulrich, A ^c   Runge, D ^c   Marinova, M ^d   Lutjohann D ^d   Kroemer, H K ^a   Siegmund, W ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Primacyt Cell Culture Technologies   (Germany)

^d UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; CARRIER PROTEIN ABCC2; CARRIER PROTEIN OATP1B1; EFAVIRENZ; EZETIMIBE; GLUCURONIDE; GLUCURONOSYLTRANSFERASE 1A1; MULTIDRUG RESISTANCE PROTEIN 1; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; GENETIC ASSOCIATION; HUMAN; HUMAN EXPERIMENT; IC 50; INTESTINE ABSORPTION; LONG TERM CARE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; ANIMALS; ANTICHOLESTEREMIC AGENTS; AZETIDINES; BENZOXAZINES; BIOLOGICAL TRANSPORT; CELL LINE; CELL LINE, TRANSFORMED; CYTOCHROME P-450 CYP3A; DOGS; DRUG INTERACTIONS; GENE EXPRESSION; GLUCURONOSYLTRANSFERASE; HEK293 CELLS; HIV INFECTIONS; HUMANS; HYPERCHOLESTEROLEMIA; INTESTINAL ABSORPTION; INTESTINES; LIVER; MALE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; ORGANIC ANION TRANSPORTERS; P-GLYCOPROTEIN; RNA, MESSENGER; YOUNG ADULT;

EID: 84857235431     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.255     Document Type: Article

References (45)

1. Thompson, M.A. et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 304, 321-333 (2010).
2. Volberding, P. et al. Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatment. AIDS 23, 1987-1995 (2009).
3. Maggiolo, F. Efavirenz: a decade of clinical experience in the treatment of HIV. J. Antimicrob. Chemother. 64, 910-928 (2009).
4. Rakhmanina, N.Y. & van den Anker, J.N. Efavirenz in the therapy of HIV infection. Expert Opin. Drug Metab. Toxicol. 6, 95-103 (2010).
5. Calza, L., Manfredi, R. & Chiodo, F. Hyperlipidaemia in patients with HIV-1 infection receiving highly active antiretroviral therapy: epidemiology, pathogenesis, clinical course and management. Int. J. Antimicrob. Agents 22, 89-99 (2003). (Pubitemid 36970166)
6. Sustiva (efavirenz) product information. New York: Bristol-Myers Squibb, 2009.
7. Bain, A.M., White, E.A., Rutherford, W.S., Rahman, A.P. & Busti, A.J. A multimodal, evidence-based approach to achieve lipid targets in the treatment of antiretroviral-associated dyslipidemia: case report and review of the literature. Pharmacotherapy 28, 932-938 (2008). (Pubitemid 351875172)
8. Fichtenbaum, C.J. Does antiretroviral therapy increase or decrease the risk of cardiovascular disease? Curr. HIV/AIDS Rep. 7, 92-98 (2010).
9. Grinspoon, S. & Carr, A. Cardiovascular risk and body-fat abnormalities in HIVinfected adults. N. Engl. J. Med. 352, 48-62 (2005). (Pubitemid 40075680)
10. Sekhar, R.V. & Balasubramanyam, A. Treatment of dyslipidemia in HIV-infected patients. Expert Opin. Pharmacother. 11, 1845-1854 (2010).
11. Gerber, J.G. et al. Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study. J. Acquir. Immune Defic. Syndr. 39, 307-312 (2005). (Pubitemid 40923210)
12. Rahman, A.P. et al. Safety and efficacy of simvastatin for the treatment of dyslipidemia in human immunodeficiency virus-infected patients receiving efavirenz-based highly active antiretroviral therapy. Pharmacotherapy 28, 913-919 (2008). (Pubitemid 351875170)
13. Faucette, S.R. et al. Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J. Pharmacol. Exp. Ther. 320, 72-80 (2007). (Pubitemid 46025721)
14. Hariparsad, N., Nallani, S.C., Sane, R.S., Buckley, D.J., Buckley, A.R. & Desai, P.B. Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital. J. Clin. Pharmacol. 44, 1273-1281 (2004). (Pubitemid 39391486)
15. H ealan-Greenberg, C., Waring, J.F., Kempf, D.J., Blomme, E.A., Tirona, R.G. & Kim, R.B. A human immunodeficiency virus protease inhibitor is a novel functional inhibitor of human pregnane X receptor. Drug Metab. Dispos. 36, 500-507 (2008). (Pubitemid 351397974)
16. Mouly, S. et al. Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin. Pharmacol. Ther. 72, 1-9 (2002). (Pubitemid 34833182)
17. Weiss, J., Herzog, M., K?ig, S., Storch, C.H., Ketabi-Kiyanvash, N. & Haefeli, W.E. Induction of multiple drug transporters by efavirenz. J. Pharmacol. Sci. 109, 242-250 (2009).
18. Smith, P.F., DiCenzo, R. & Morse, G.D. Clinical pharmacokinetics of nonnucleoside reverse transcriptase inhibitors. Clin. Pharmacokinet. 40, 893-905 (2001). (Pubitemid 34066687)
19. Ngaimisi, E. et al. Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients. Clin. Pharmacol. Ther. 88, 676-684 (2010).
20. Bennett, M.T., Johns, K.W. & Bondy, G.P. Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV. Lipids Health Dis. 6, 15 (2007).
21. Berg-Wolf, M.V., Klibanov, O.M., Gaughan, J.P. & Tedaldi, E.M. Ezetimibe combined with low-dose statin effectively lowers LDL in protease inhibitor treated patients. AIDS Patient Care STDs 22, 483-488 (2008).
22. Chow, D. et al. Short-term ezetimibe is well tolerated and effective in combination with statin therapy to treat elevated LDL cholesterol in HIVinfected patients. AIDS 23, 2133-2141 (2009).
23. Coll, B., Aragon, G., Parra, S., Alonso-Villaverde, C. & Masana, L. Ezetimibe effectively decreases LDL-cholesterol in HIV-infected patients. AIDS 20, 1675-1677 (2006). (Pubitemid 44162414)
24. Negredo, E. et al. Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins. AIDS 20, 2159-2164 (2006). (Pubitemid 44684706)
25. Wohl, D.A. et al. Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy. Clin. Infect. Dis. 47, 1105-1108 (2008).
26. Kosoglou, T., Statkevich, P., Johnson-Levonas, A.O., Paolini, J.F., Bergman, A.J. & Alton, K.B. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin. Pharmacokinet. 44, 467-494 (2005). (Pubitemid 40733733)
27. Oswald, S. et al. Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC 2), and uridine diphosphateglucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans. Clin. Pharmacol. Ther. 79, 206-217 (2006).
28. Oswald, S. et al. Disposition of ezetimibe is influenced by polymorphisms of the hepatic uptake carrier OATP1B1. Pharmacogenet. Genomics 18, 559-568 (2008).
29. Storch, C.H., Theile, D., Lindenmaier, H., Haefeli, W.E. & Weiss, J. Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem. Pharmacol. 73, 1573-1581 (2007). (Pubitemid 46527547)
30. Urquhart, B.L., Tirona, R.G. & Kim, R.B. Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs. J. Clin. Pharmacol. 47, 566-578 (2007). (Pubitemid 46632158)
31. Weiss, J., Theile, D., Ketabi-Kiyanvash, N., Lindenmaier, H. & Haefeli, W.E. Inhibition of MRP1/ABCC 1, MRP2/ABCC 2, and MRP3/ABCC 3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors. Drug Metab. Dispos. 35, 340-344 (2007). (Pubitemid 46333919)
32. Oscarson, M. et al. Effects of rifampicin on global gene expression in human small intestine. Pharmacogenet. Genomics 17, 907-918 (2007). (Pubitemid 350293791)
33. Hariparsad, N., Carr, B.A., Evers, R. & Chu, X. Comparison of immortalized Fa2N-4 cells and human hepatocytes as in vitro models for cytochrome P450 induction. Drug Metab. Dispos. 36, 1046-1055 (2008). (Pubitemid 351717461)
34. Josephson, F. et al. CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4beta-hydroxycholesterol levels. Eur. J. Clin. Pharmacol. 64, 775-781 (2008).
35. Oswald, S. et al. Disposition and sterol-lowering effect of ezetimibe are influenced by single-dose coadministration of rifampin, an inhibitor of multidrug transport proteins. Clin. Pharmacol. Ther. 80, 477-485 (2006). (Pubitemid 44767877)
36. B?anger, A.S., Caron, P., Harvey, M., Zimmerman, P.A., Mehlotra, R.K. & Guillemette, C. Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine. Drug Metab. Dispos. 37, 1793-1796 (2009).
37. Oswald, S. et al. Pharmacokinetic and pharmacodynamic interactions between the immunosuppressant sirolimus and the lipid-lowering drug ezetimibe in healthy volunteers. Clin. Pharmacol. Ther. 87, 663-667 (2010).
38. Oswald, S. et al. Drug interactions between the immunosuppressant tacrolimus and the cholesterol absorption inhibitor ezetimibe in healthy volunteers. Clin. Pharmacol. Ther. 89, 524-528 (2011).
39. Kastelein, J.J. et al. Simvastatin witHor without ezetimibe in familial hypercholesterolemia. N. Engl. J. Med. 358, 1431-1443 (2008). (Pubitemid 351482735)
40. Rosseb A.B. et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N. Engl. J. Med. 359, 1343-1356 (2008).
41. Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am. Heart J. 160, 785-794 (2010).
42. Ogburn, E.T., Jones, D.R., Masters, A.R., Xu, C., Guo, Y. & Desta, Z. Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation. Drug Metab. Dispos. 38, 1218-1229 (2010).
43. Oswald, S., Scheuch, E., Cascorbi, I. & Siegmund, W. A LC-MS/MS method to quantify the novel cholesterol lowering drug ezetimibe in human serum, urine and feces in healthy subjects genotyped for SLCO1B1. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 830, 143-150 (2006). (Pubitemid 41831400)
44. Thelen, K.M., Laaksonen, R., Pv H., Lehtimi, T. & Ljohann, D. Highdose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels. J. Clin. Pharmacol. 46, 812-816 (2006). (Pubitemid 43882805)
45. L?johann, D. et al. 4beta-hydroxycholesterol as a marker of CYP3A4 inhibition in vivo-effects of itraconazole in man. Int. J. Clin. Pharmacol. Ther. 47, 709-715 (2009).